Phase 1 Clinical Trials2024-09-25T10:48:17-04:00

Phase 1 Clinical Trials

Early-phase CNS studies are unique; and very different from trials in other indications that don’t involve the brain.  Drug, device, and technology developers working in psychiatric and neurological indications must document CNS activity, safety, pharmacokinetics, and pharmacodynamics.  It takes a company with the right expertise to deliver early-phase data that launches an investigational new treatment into late-phase clinical development.

At Clinilabs, we use our phase 1 unit to accelerate the development of these programs so our customers can get new treatments to market faster.  From simple FIH/SAD/MAD studies to complex biomarker, kinetic/dynamic, proof-of-concept, and global multicenter projects, we have it all to ensure that your development program moves swiftly and seamlessly from early-phase to late-phase clinical trials.
Impeccable execution.  Quality.  Speed.  Enabled by unparalleled CNS project teams.
  • First in human

  • First in class

  • Single ascending dose (SAD)

  • Multiple ascending dose (MAD)

  • Bioequivalence (BE)

  • Drug – drug interaction studies

  • Drug – alcohol interactions studies

  • Food effect studies

  • Pharmacokinetic (PK) studies

  • Pharmacodynamic (PD) studies

  • Kinetic-dynamic relationships

Go to Top